

# Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)

**First published:** 02/02/2019

**Last updated:** 23/10/2025

Study

Planned

## Administrative details

### EU PAS number

EUPAS27851

---

### Study ID

27852

---


### DARWIN EU® study

No


---

### Study countries

 Belgium

 Denmark

 Italy

 Netherlands



Spain



Switzerland



United Kingdom



United States

---

## Study description

**Rationale and Background:** To increase readiness of European data sources to conduct multi-site vaccine coverage, benefit and risk studies  
**Research Question and Objective:** The primary objective is to determine exposure in the population, and coverage of routine vaccinations in children and elderly. The secondary objective is to coverage estimates with external benchmarks  
**Study Design:** The main study design is a retrospective dynamic cohort study  
**Population:** The source population comprises of all subjects registered with one of the ADVANCE participating databases, which can link vaccination and population data and have provided their willingness to participate. The study population comprises all persons who are registered during the study period that starts January 1, 2000 and ends December 31, 2018.  
**Outcome Parameters:** Vaccine exposure and vaccine coverage  
**Data Sources:** Electronic health care databases (vaccine registries, record linkage, surveillance and GP based databases) currently available in the ADVANCE consortium and eligible are located in Denmark, Spain, Italy, UK and Netherlands  
**Informative data sources**  
**Vaccine schedules:** European Centre for Disease Prevention and Control (ECDC) vaccine schedules in Europe and national statistics on vaccination coverage  
**Benchmark data:** WHO estimates for following vaccines/doses in a country: BCG, DTP1, DTP3, HepB\_BD, HepB3, Hib3, IPV1, MCV1, MCV2, PCV3, Pol3, RCV1, Rota, [http://apps.who.int/immunization\\_monitoring/globalsummary/timeseries/tswucoveredtp](http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveredtp) literature for HPV (Bruni, Lancet Global Health) and influenza (VENICE)

---


## Study status


Planned


## Research institutions and networks


## Institutions


### P95 Clinical and Epidemiology Services


 Belgium

 Colombia

 Netherlands

 South Africa

 Thailand

 United States

**First published:** 07/11/2022

**Last updated:** 21/02/2025

**Institution**

Laboratory/Research/Testing facility

Non-Pharmaceutical company

ENCePP partner

### VACCINE.GRID

 Switzerland


**First published:** 26/06/2012

**Last updated:** 20/08/2024

**Institution**

Not-for-profit

Aarhus University & Aarhus University Hospital  
DEPARTMENT OF CLINICAL EPIDEMIOLOGY

 Denmark

**First published:** 20/07/2021


**Last updated:** 02/04/2024

**Institution**

Educational Institution

ENCePP partner

## University Medical Center Utrecht (UMCU)

 Netherlands

**First published:** 24/11/2021

**Last updated:** 22/02/2024


**Institution**

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

## Centre for Health Protection (RIVM-GZB), National Institute for Public Health & Environment

 Netherlands

**First published:** 06/11/2022

**Last updated:** 30/03/2026

**Institution**

EU Institution/Body/Agency

Laboratory/Research/Testing facility

ENCePP partner

## P95 Clinical and Epidemiology Services

-  Belgium
-  Colombia
-  Netherlands
-  South Africa
-  Thailand
-  United States

**First published:** 07/11/2022

**Last updated:** 21/02/2025

**Institution**

**Laboratory/Research/Testing facility**

**Non-Pharmaceutical company**

**ENCePP partner**

## Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

-  Spain

**First published:** 05/10/2012

**Last updated:** 23/05/2025

**Institution**

**Educational Institution**

**Laboratory/Research/Testing facility**

**Not-for-profit**

**ENCePP partner**

## Pfizer

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

## Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

 Spain

**First published:** 01/02/2024

**Last updated:** 04/09/2024

**Institution**

**EU Institution/Body/Agency**

**Not-for-profit**

**Regulatory Authority**

**ENCePP partner**

Sciensano Brussels, RIVM the Netherlands, RCGP-RSC United Kingdom, PEDIANET Italy, ATS-Valpadana Italy, Pfizer USA

## Networks

## Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE)

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Network

## Pedianet network (So.Se.Te)

 Italy

**First published:** 23/10/2025

**Last updated:** 08/04/2026

Network

## Contact details

### Study institution contact

Miriam Sturkenboom [m.c.j.sturkenboom@umcutrecht.nl](mailto:m.c.j.sturkenboom@umcutrecht.nl)

Study contact

[m.c.j.sturkenboom@umcutrecht.nl](mailto:m.c.j.sturkenboom@umcutrecht.nl)

### Primary lead investigator

Miriam Sturkenboom

Primary lead investigator

# Study timelines

## **Date when funding contract was signed**

Planned: 01/10/2013

Actual: 01/10/2013

---

## **Study start date**

Planned: 01/02/2019

---

## **Data analysis start date**

Planned: 02/02/2019

---

## **Date of interim report, if expected**

Planned: 31/03/2019

---

## **Date of final study report**

Planned: 31/03/2019

# Sources of funding

- EU institutional research programme

# More details on funding

Innovative Medicines Initiative

# Study protocol

[ADVANCEPOC\\_2protocolv1.020190201\\_clean.pdf](#) (744.23 KB)

# Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Drug utilisation

**Main study objective:**

To assess exposure and coverage to routine vaccinations

### Study Design

**Non-interventional study design**

Cohort

### Study drug and medical condition

## **Anatomical Therapeutic Chemical (ATC) code**

(J07B) VIRAL VACCINES

VIRAL VACCINES

## Population studied

### **Age groups**

- Preterm newborn infants (0 - 27 days)
- Term newborn infants (0 - 27 days)
- Infants and toddlers (28 days - 23 months)
- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

### **Estimated number of subjects**

35000000

## Study design details

### **Outcomes**

Counts and coverage, Comparisons against WHO benchmarks

---

### **Data analysis plan**

Exposure and coverage estimation using point prevalence, point prevalence adjusted for follow-up and cumulative distribution function

Data management

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

Danish registries (access/analysis)

The Information System for Research in Primary Care (SIDIAP)

BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)

ARS Toscana

Pedianet

---

### Data source(s), other

Danish Registries (access/analysis), SIDIAP, BIFAP, ARS, Pedianet

---

### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Electronic healthcare records \(EHR\)](#)

[Other](#)

---

### Data sources (types), other

Exposure registry

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No